We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novartis Signs $570 Million Deal for New Hepatitis Treatment
Novartis Signs $570 Million Deal for New Hepatitis Treatment
June 2, 2005
Novartis has inked a deal with San Diego-based biotechnology company Anadys Pharmaceuticals to develop, manufacture and commercialize ANA975, a new treatment for the hepatitis C virus (HCV).